A prospective, randomized, open-label clinical trial evaluating the effect of sarpogrelate hydrochloride on skin perfusion pressure in hemodialysis patients with arteriosclerosis obliterans

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2010
INTERVENTION: Patients will be randomly assigned either to sarpogrelate hydrochloride or conventional therapy. Sarpogrelate hydrochloride 300mg daily for a year Conventional therapy CONDITION: Chronic kidney disease PRIMARY OUTCOME: Change in SPP SECONDARY OUTCOME: Improvement of symptoms of ASO; Change in ABI; Adverse event INCLUSION CRITERIA: 1)Hemodialysis patients with arteriosclerosis obliterans(Fontaine1)2)SPP<75mmHg at the commencement
Epistemonikos ID: b68f9f2d1acad4b7f882acc327776f9756cb4416
First added on: Aug 22, 2024